Papers

Research literature with structured metadata.

Trials

Registered studies by status, phase, and compound.

Topics

Indications and themes psychedelics are researched for.

Compounds

Evidence across molecules with rich data.

Countries

Regulation, access, and research activity by region.

Stakeholders

Organizations shaping the space across research, policy, and funding.

People

Investigators, clinicians, and authors with mapped output.

Courses

Training programs and certifications across modalities.

Events

Conferences, workshops, and convenings by date and focus.

Results

Compare outcome data across trials and publications.

Research Snapshot

One-page overview of trials, participants, papers, and research networks.

Clinical Guidelines

Trial-anchored manuals and protocol guidance with competency mapping.

Research recaps

Monthly evidence summaries with key takeaways.

Map of research

Landscape view of trials, compounds, and outcomes.

Newsletter

Weekly or daily updates on trials, publications, analysis, and more.

Research Groups

Worldwide map of psychedelic research centres by region.

Road to Access

Science, regulation, and economics on the path to patient access.

Research Network

Interactive co-authorship map of psychedelic researchers.

Top papers

Find needles in the haystack of psychedelic research per topic.

AskBeta
Pricing

The intelligence layer for psychedelic research.

Company

  • About
  • Contact
  • Newsletter

Product

  • Feedback
  • Roadmap
  • Changelog
  • API
  • Partners
  • Clinical Guidelines

Legal

  • Privacy
  • Terms

© 2026 Blossom. All rights reserved.

Home/Research/Placebo/Tobacco/Nicotine Use Disorder (TUD)

Placebo for Tobacco/Nicotine Use Disorder (TUD)

2 papers and 4 clinical trials exploring placebo as a treatment for tobacco/nicotine use disorder (tud).

CompoundComparator / Control

Placebo

Placebo is the most widely referenced comparator in psychedelic clinical research, appearing in over 500 trials. Understanding how placebos are designed, administered, and interpreted is essential to evaluating the evidence base for psychedelic-assisted therapies — and one of the field’s most contested methodological challenges.

Full Placebo profile
Indication1.3 billion smokers worldwide.

Tobacco/Nicotine Use Disorder (TUD)

Tobacco Use Disorder (TUD) presents significant challenges for public health, and emerging research indicates that psychedelic compounds may offer novel therapeutic avenues for treatment. Initial studies highlight the potential of psychedelics like ayahuasca and ibogaine in reducing tobacco dependence.

Full Tobacco/Nicotine Use Disorder (TUD) profile

Academic Research

2 papers
Open Accessindividual

Effects of a Single Sub-Anesthetic Dose of Ketamine in Tobacco Use Disorder: An Active-Placebo, Randomized Crossover Study

This randomised crossover study (n=18) tested a single sub-anesthetic ketamine infusion against midazolam in adults with tobacco use disorder who were not trying to quit smoking. Ketamine was well tolerated but did not clearly reduce smoking, craving or withdrawal, although some participants reported stronger psychological effects and found abstaining easier afterwards.

Published
April 30, 2026
Journal
Brain Sciences
Authors
Luzum, N. R., McCall, M. H., Talley Boyd, C., Columbano, H., Ip, E., Saldana, S., Oliveto, A. H., Addicott, M.
Open Accessmeta

Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects

This pooled analysis (n=139) of double-blind, placebo-controlled studies reviews the role of genetic polymorphisms in CYP2C19, CYP2B6, and CYP1A2 in the metabolism of MDMA in humans. The research shows affirmed that these enzymes play a significant role in the metabolism of MDMA to MDA in humans and that genetic polymorphism in CYP2C19 could moderate MDMA's cardiovascular toxicity.

Published
March 1, 2017
Journal
European Neuropsychopharmacology
Authors
Vizeli, P., Schmid, Y., Prestin, K., Meyer Zu Schwabedissen, H. E., Liechti, M. E.

Clinical Trials

4 trials
CompletedPhase I

The Effects of Sedatives on Tobacco Use Disorder Version 2 (SED-TUD2)

This double-blind, randomised, placebo-controlled, crossover mechanistic trial (n=52) tested single IV infusions of ketamine (0.71 mg/kg), midazolam (0.025 mg/kg), dexmedetomidine (0.025 mg/kg), or saline in non-treatment-seeking smokers.

Started
January 31, 2023
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
NCT05505630
RecruitingPhase II

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Double-blind, randomised, multi-site trial (n=66) comparing two psilocybin sessions (30 mg; second session 30 or 40 mg) versus active placebo niacin (150 mg; second session 150 or 200 mg) plus CBT for smoking cessation.

Started
August 1, 2022
Type
interventional
Blinding
quadruple
Randomized
Yes
Registry ID
NCT05452772
CompletedPhase I

A study on the safety and effects of the drug DMT in healthy smoking individuals

Randomised, double-blind, placebo-controlled Phase I single ascending dose IV infusion study (n=50) assessing safety, PK/PD and tolerability of target-controlled DMT infusion in healthy smokers.

Started
January 8, 2021
Type
interventional
Blinding
double
Randomized
Yes
Registry ID
ISRCTN11577984
CompletedPhase NA

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

Randomised, parallel-group study (n=82 actual) comparing a single high-dose psilocybin session (30 mg/70 kg) plus CBT versus standard transdermal nicotine patch plus CBT for nicotine-dependent smokers.

Started
September 1, 2008
Type
interventional
Blinding
none
Randomized
Yes
Registry ID
NCT01943994

Explore further

Search all Placebo papers Search all Tobacco/Nicotine Use Disorder (TUD) trials Full Placebo profile Full Tobacco/Nicotine Use Disorder (TUD) profile